|1.||Leffler, Charles W: 4 articles (06/2012 - 09/2003)|
|2.||Parfenova, Helena: 4 articles (06/2012 - 09/2003)|
|3.||Ferrándiz, Maria Luisa: 4 articles (05/2012 - 01/2005)|
|4.||Alcaraz, Maria José: 3 articles (12/2011 - 01/2005)|
|5.||Tsai, Pei-Shan: 3 articles (06/2011 - 05/2007)|
|6.||Huang, Chun-Jen: 3 articles (06/2011 - 05/2007)|
|7.||Amon, Michaela: 3 articles (04/2007 - 02/2003)|
|8.||Menger, Michael D: 3 articles (04/2007 - 02/2003)|
|9.||Carratu, Pierluigi: 3 articles (06/2005 - 09/2003)|
|10.||Braza-Boïls, Aitana: 2 articles (05/2012 - 09/2011)|
02/01/1986 - "The effect of a single prophylactic dose of tin protoporphyrin on the carbon monoxide (CO) excretion rate of antibiotic-treated neonatal rats before and after hematoma formation was evaluated. "
08/01/1985 - "Effect of tin protoporphyrin on the excretion rate of carbon monoxide in newborn rats after hematoma formation."
02/01/1986 - "These studies demonstrate that tin protoporphyrin is an effective in vivo inhibitor of endogenous heme catabolism as measured by the CO excretion rate in antibiotic-treated neonatal rats with and without artificially created hematomas."
02/01/1986 - "The CO excretion rate, reflecting the rate of bilirubin production, of tin protoporphyrin-treated (TP-H) rats 24 hours after injection of 65 mole of tin protoporphyrin per kilogram (time [t] = 0 hours) was approximately 18% lower than those of the saline-control (S-C) and saline-hematoma (S-H) rats, but this difference was no longer evident at t = 43 hours. "
08/01/1985 - "This study evaluated the efficacy of tin protoporphyrin (TP), a competitive inhibitor of heme oxygenase, in suppressing the total body excretion rate of carbon monoxide (CO), an index of total bilirubin formation, in neonatal rats with artificially created hematomas. "
06/01/1992 - "However, if it can be shown that tin-protoporphyrin can serve as a safe and less costly alternate treatment, a considerable improvement in the management of neonatal jaundice would be achieved."
01/01/1990 - "However, if it can be shown that the use of tin-protoporphyrin can serve as a safe and less costly alternate treatment, a considerable improvement in the management of neonatal jaundice will be achieved."
09/01/1987 - "Tin-protoporphyrin and neonatal jaundice."
09/24/1982 - "Chemoprevention of neonatal jaundice: potency of tin-protoporphyrin in an animal model."
02/01/1993 - "The heme oxygenase inhibitor, tin protoporphyrin, is being studied for the prevention of neonatal jaundice. "
|3.||Hepatic Porphyrias (Hepatic Porphyria)
12/01/1985 - "Sn-protoporphyrin suppresses chemically induced experimental hepatic porphyria. "
08/01/1993 - "Tin protoporphyrin prolongs the biochemical remission produced by heme arginate in acute hepatic porphyria."
07/27/1991 - "Haem-arginate plus tin-protoporphyrin for acute hepatic porphyria."
12/01/1985 - "These findings in a rat model of hepatic porphyria suggest that Sn-protoporphyrin may be useful in the treatment of acute exacerbations of "inducible" hepatic porphyrias in man, especially since Sn-protoporphyrin, unlike hematin which is presently used for this purpose, is neither degraded by nor induces the activity of heme oxygenase."
06/01/1989 - "Administration of both tin-protoporphyrin and tin-mesoporphyrin resulted in decreases in the urinary excretion of heme pathway intermediates in stable hyperexcreters with acute hepatic porphyria."
|4.||Psoriasis (Pustulosis Palmaris et Plantaris)
06/03/1989 - "Sn-protoporphyrin with conventional UVA light may be useful in the treatment of psoriasis."
01/01/1989 - "As shown in this study, one-day treatment with Sn-protoporphyrin followed by conventional UVA light treatment may be a useful therapeutic modality for psoriasis patients and merits further investigation."
06/03/1989 - "Tin-protoporphyrin and long wave length ultraviolet light in treatment of psoriasis."
06/03/1989 - "To assess the effects of tin (Sn)-protoporphyrin (a synthetic haem analogue) in conjunction with long wave length ultraviolet light (UVA) radiation in psoriasis 10 patients, 9 of whom were substantially or completely unresponsive to other forms of therapy, received 2.0 mumol/kg bodyweight of Sn-protoporphyrin for 1 day followed by UVA light treatment for 21 days. "
11/01/1996 - "We have reviewed the results of clinical investigations into the use of photodynamic therapy (PDT) with intravenous injection of hematoporphyrin derivative (HpD), Photofrin (PF) and Sn-protoporphyrin (Sn-Pp) or oral administration of delta-aminolevulinic acid in the treatment of skin cancers and/or psoriasis. "
05/01/2000 - "Hemin-induced vessel relaxation and CO production was inhibited by HO inhibitor, tin protoporphyrin IX. Our findings establish HO-1 as an endogenous system that offers protection against cytotoxic damage in the placenta, identifies the HO-CO pathway to regulate feto-placental circulation and provides a new approach to study the disease of preeclampsia."
|1.||Heme Oxygenase (Decyclizing) (Heme Oxygenase)
|6.||glucuronyl glucosamine glycan sulfate (Vessel)
|8.||Small Interfering RNA (siRNA)
|2.||Phototherapy (Light Therapy)